The American Society of Clinical Oncology (ASCO) has announced the candidates for its 2025 election. The ASCO Nominating Committee has selected 13 distinguished members to run for open positions across the Society’s governance structure.
Eligible ASCO members are invited to cast their ballots and play a role in shaping the future of oncology leadership.
Voting Information
Voting is open to eligible ASCO members, those holding a doctoral-level degree (MD, DO, PhD, PharmD, DMedSc, DNSc, DNP, or equivalent) and in good standing as of October 19, 2025.
Members who participate in the election will also earn a FASCO point for their engagement.
All ballots, whether online or paper, must be submitted by Monday, December 8, 2025, at 3:00 PM (EST). Election results will be announced in mid-December 2025, and newly elected leaders will assume their roles in June 2026.
President-Elect
| Images | Name |
|---|---|
 | Deb Schrag, MD, MPH, FASCOMemorial Sloan Kettering Cancer Center Dr. Schrag is a gastrointestinal medical oncologist who currently serves as Chair of the Department of Medicine at Memorial Sloan Kettering and as Professor of Medicine at Weill Cornell Medical College in New York City. She is a population scientist and health services researcher who has worked to improve the quality, effectiveness and experience of cancer care. She attended Medical School at Columbia Presbyterian, trained in Internal Medicine at the Brigham and Women’s Hospital and completed her fellowship at the Dana Farber Cancer Institute. Prior to MSK, she served as Chief of the Division of Population Sciences at Dana Farber and as Professor of Medicine at Harvard Medical School. She has served ASCO in a variety of roles including chair for the Health Services Committee and as a member of the Annual Meeting Scientific Program Committee, Quality and Practice Guidelines Committee, the Joint Special Awards Selection Committee, and as mentor for the Leadership Develop Program and member of the ASCO Board of Directors. |
Board of Directors – Designated Community Oncologist
| Images | Name |
|---|---|
 | Piyush Srivastava, MD, FASCOKaiser Permanente Dr. Srivastava is a gastrointestinal oncologist and palliative care physician with extensive leadership experience within ASCO. He has served as Chair of the Clinical Practice Committee, Government Relations Committee, and Clinician Well-Being Task Force, and currently chairs the Practice Quality Improvement Steering Group. He also serves on the Health Policy Committee and is a long-standing faculty member and coach for ASCO’s Quality Training Program. A graduate of ASCO’s Leadership Development Program, Dr. Srivastava now serves as a mentor and coach, reflecting his ongoing commitment to advancing quality and leadership in oncology care delivery. |
 | Dan Zuckerman, MD, FASCOSt. Luke’s Cancer Institute Dr. Zuckerman is the co-director of Oncology Research, director of GI Oncology and staff medical Oncologist/Hematologist at St. Luke’s Cancer Institute. He has served as president of the Idaho Society of Clinical Oncology (ISCO) and is a past chair of the ASCO Clinical Practice and Innovation Committee. He has also served as a member of various other ASCO volunteer groups, including the Quality of Care Committee, the Nominating Committee, and the Annual Meeting Education Program Committee. |
Board of Directors – Designated International Oncologist
| Images | Name |
|---|---|
 | Herbert Ho-fung Loong, MBBS, FRCP, FASCOThe Chinese University of Hong Kong, Hong Kong SAR, China Dr. Loong is Clinical Associate Professor in the Department of Clinical Oncology and Medical Director (Oncology) of Phase 1 Clinical Trial Centre at The Chinese University of Hong Kong. He is also a Board member on the Specialty Board in Medical Oncology, Hong Kong College of Physicians, a member of the Cancer Expert Working Group, Department of Health, The Government of the Hong Kong SAR. Among his various volunteer work, he is the current Past Chair of the International Affairs Committee of ASCO and has served on the Annual Meeting Scientific Program Committee and Breakthrough Program Committee. He currently co-chairs the Asia Pacific Oncology Drug Development Consortium (APODDC) and Asia Pacific Coalition Against Lung Cancer (APCLC) and is a former Board Member of the Connective Tissue Oncology Society (CTOS). He holds the rank of Specialist Flight Lieutenant in the Hong Kong Air Cadet Corps. |
 | C. S. Pramesh, MBBS, MS, FRCSTata Memorial Center, India Dr. Pramesh is Director at Tata Memorial Hospital, Convener at the National Cancer Grid, and a Professor at the Division of Thoracic Surgical Oncology, Tata Memorial Centre, Mumbai, India. He is also a Visiting Professor, Division of Cancer Studies, Faculty of Life Sciences and Medicine at King’s College London and on the academic faculty at the Institute of Cancer Policy, King’s Health Partners Integrated Cancer Centre, UK. Dr. Pramesh has served as a member of various ASCO volunteer groups including the International Affairs Committee, the Annual Meeting Scientific Program Committee, the MCMC Working Group and the International Education Steering Group. His work on reducing inequities in cancer control through the National Cancer Grid was recognized by the United States National Cancer Institute with the Rachel Pearline Global Cancer Research Humanitarian award. |
Board of Directors – Designated Radiation Oncologist
| Images | Name |
|---|---|
 | Melvin L.K. Chua, PhD, MBBS, FRCR, FASCONational Cancer Centre Singapore Dr. Chua serves a joint appointment at the National Cancer Centre Singapore (NCCS) and the Duke-NUS Medical School. He is an Associate Professor (on tenure) of Duke-NUS Medical School, Singapore, visiting professor of the Zhongnan Hospital of Wuhan University, China, and Principal Investigator of the Precision Radiotherapeutics and Oncology Program (PROP). Additionally, he is the Head of Department and Senior Consultant for the Department of Head and Neck and Thoracic Radiation Oncology and Director of the Data and Computational Science Hub at the NCCS. He is also the Commissioner of the International Commission of Radiation Units and Measurements (ICRU), and Commissioner representative for Singapore on the Lancet Oncology Commission on Cancer in the Commonwealth. He is an active volunteer with ASCO including serving as council member and past Chair of the ASCO Asia Pacific Regional Council (RC) and Program Chair for the ASCO Breakthrough Meeting 2024. He has also served as Mentor of ASCO Asia Pacific the Leadership Development Program. |
 | Karyn A. Goodman, MD, MS, FASTRO, FACR, FASCOIcahn School of Medicine at Mount Sinai Dr. Goodman is a professor and vice chair of Radiation Oncology with a dual appointment as professor of medicine in the Division of Hematology and Oncology at the Icahn School of Medicine at Mount Sinai. She serves as the Associate Director of Clinical Research in the Tisch Cancer Institute. She has served as a member of various ASCO volunteer groups including the Gastrointestinal Guideline Advisory Group, the GI Cancers Symposium Steering Committee, the Annual Meeting Scientific Program Committee, and the ASCO/AACR Methods in Clinical Cancer Research Workshop. |
Board of Directors – Undesignated Member
| Images | Name |
|---|---|
 | Dawn L. Hershman, MD, MS, FASCOColumbia University Dr. Hershman is a professor of Medicine and Epidemiology with tenure at Columbia University College of Physicians & Surgeons and attending at New York-Presbyterian/Columbia University Medical Center. She is chief for the Division of Hematology and Oncology at Columbia University Medical Center and deputy director at the Herbert Irving Comprehensive Cancer Center. She is the incoming co-chair of the SWOG Cancer Research Network. Her numerous ASCO volunteer appointments include serving as chair of the Quality Care Symposium Planning Committee and the Conquer Cancer Foundation Grants Selection Committee as well as co-chair of the CDK Study Advisory Group. She is a graduate of the Leadership Development Program, and in 2025 she was honored with the ASCO David Karnofsky Science of Oncology Award. |
 | W. Kimryn Rathmell, MD, PhD, FASCOArthur James Cancer Hospital - The Ohio State University Dr. Rathmell is the CEO of the Ohio State University Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. She has had a multitude of ASCO volunteer service roles, including serving as chair of the Nominating Committee and as a member of groups including the Annual Meeting Education Committee, Career Development Committee and Ethics Committee. She is also a graduate of the Leadership Development Program. |
Nominating Committee – Undesignated Member
| Images | Name |
|---|---|
 | Neeraj Agarwal, MD, FASCOHuntsman Cancer Institute, University of Utah Dr. Agarwal is the senior director (aka associate director) of the cancer center for clinical research, professor in the Department of Internal Medicine (Medical Oncology), Huntsman Cancer Institute (HCI) Presidential Endowed Chair of Cancer Research, director of Genitourinary Oncology in the Division of Medical Oncology HCI, and director of the Center of Investigational Therapeutics HCI at the Huntsman Cancer Institute, University of Utah. He is a member of many volunteer committees including the Patient Information Advisory Committee and the Cancer Communications Committee. Dr. Agarwal is also the current editor-in-chief of the ASCO Daily News. |
 | Wells A. Messersmith, MD, FACP, FASCOUniversity of Colorado Dr. Messersmith is a professor of Medicine at the University of Colorado School of Medicine, head of the Division of Medical Oncology, Dept of Medicine, and chief medical officer of Oncology Services at UCHealth. He is also associate director for Clinical Services at the University of Colorado Cancer Center (UCCC), and national director for the Academic GI Cancer Consortium (AGICC). His ASCO volunteer work includes serving as Chair of the ASCO Leadership Development Program, Chair of GI/Colorectal Subcommittee for the Scientific Review Committee for the 2025 ASCO Annual Meeting and a member of various committees including the Best of ASCO Planning Committee, Conquer Cancer Foundation Grants Selection Committee and GI Cancers Symposium Program Committee. He is also a graduate of the Leadership Development Program. |
 | Mina S. Sedrak, MD, MS, FASCODavid Geffen School of Medicine at UCLA Dr. Sedrak is a medical oncologist and Associate Professor of Medicine with tenure at the David Geffen School of Medicine at UCLA. He co-leads the Cancer Control and Survivorship Program at the UCLA Health Jonsson Comprehensive Cancer Center and serves as Director of the UCLA Cancer and Aging Program. He is Chair of the ASCO Clinical Research Committee, Co-Chair of the Improving the Evidence Base for Older Adults with Cancer Task Force, and Track Leader of the Quality Care and Health Services Research Track in the Annual Meeting Scientific Program Committee. Dr. Sedrak is also a current member of the CDK4/6 Inhibitor Dosing Knowledge (CDK) Study Advisory Group, a former member of the Geriatric Oncology Track in the Education Program Committee, and previously served as Track Leader of the Symptoms and Survivorship Track in the Annual Meeting Scientific Program Committee. He is a graduate of the ASCO Leadership Development Program. |
 | Ana I. Velázquez Mañana, MD, MSc, FASCOUniversity of California, San Francisco Dr. Velázquez Mañana is an Assistant Professor of Clinical Medicine in the Division of Hematology/Oncology at the University of California, San Francisco (UCSF) and a medical oncologist at UCSF Health and San Francisco General Hospital. She serves as Assistant Director of the Office of Education and Training of the UCSF Helen Diller Family Comprehensive Cancer Center. Dr. Velázquez Mañana has served as Chair of the ASCO Trainee and Early Career Advisory Group and as a member of the Annual Meeting Scientific Program Committee, the Cancer Care Impact Committee, the Stage IV Non-Small Cell Lung Cancer Living Guideline Panel, the Clinical Trials Access Task Force, and the Social Media Working Group. She is also an active member of the IASLC Communications Committee and the NCCN Advancing Access to Cancer Care for All Forum. |
Shaping ASCO’s Future
The ASCO Election represents a pivotal moment for the oncology community, providing members the opportunity to shape the Society’s future leadership and direction.
Eligible members are encouraged to participate and ensure that ASCO continues to advance excellence in cancer research, education, and patient care worldwide.
Voting closes December 8, 2025, at 3:00 PM (EST).
Written by Nare Hovhannisyan, MD